# The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

> **NCT05798845** · PHASE2 · RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 124 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **RADIATION:** SBRT+LDRT
- **DRUG:** Toripalimab
- **DRUG:** Chemotherapy drug
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT05798845
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-20
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05798845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05798845, "The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05798845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*